Compare ARCT & HRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARCT | HRTX |
|---|---|---|
| Founded | 2013 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 193.8M | 228.3M |
| IPO Year | 2019 | 2007 |
| Metric | ARCT | HRTX |
|---|---|---|
| Price | $7.26 | $0.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 2 |
| Target Price | ★ $24.11 | $4.50 |
| AVG Volume (30 Days) | 439.6K | ★ 3.7M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $82,031,000.00 | ★ $154,904,000.00 |
| Revenue This Year | N/A | $15.28 |
| Revenue Next Year | $12.77 | $20.29 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.36 |
| 52 Week Low | $5.85 | $0.38 |
| 52 Week High | $24.14 | $2.28 |
| Indicator | ARCT | HRTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.80 | 34.16 |
| Support Level | $6.79 | $0.38 |
| Resistance Level | $7.93 | $0.46 |
| Average True Range (ATR) | 0.43 | 0.03 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 37.50 | 66.36 |
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.